Parth Shah, MD
Hematology & Oncology · Lebanon, NHNPI 1891177796
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 39.4% of the total. Among hematology & oncology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $874.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- Boehringer Ingelheim International GmbH$6K
- E.r. Squibb & Sons, L.L.C.$2K
- Janssen Scientific Affairs, LLC$2K
- Illumina, Inc.$1K
- Gilead$190
- plus $125 from 1 others
Across 38 payments — averaging $13,316 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$300K
- Janssen Research & Development, LLC$206K
What the payments were for
- Consulting fees$8,12244%
- Speaking & faculty fees$6,30234%
- Travel & lodging$2,15512%
- Food & beverage$1,1997%
- Gifts$5813%
- Entertainment$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 10 | $7,230 |
| Boehringer Ingelheim International GmbH | 1 | $6,302 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,779 |
| Janssen Scientific Affairs, LLC | 1 | $1,650 |
| Illumina, Inc. | 5 | $1,095 |
| Gilead | 2 | $190 |
| Legend Biotech USA Inc. | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,370 in reported general payments places this provider in the 95th percentile of 61 hematology & oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 11 | $395,235 |
| Acyclovir | 37 | $308 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lebanon
- Frederick LansiganLebanon$23K
- Konstantin DragnevLebanon$5K
- Keisuke ShiraiLebanon$5K
- Ivy Riano MonsalveLebanon$2K
- Kenneth MeehanLebanon$711
- John HillLebanon$687
- Young Soo RhoLebanon$475
- Gabriella HarmonLebanon$273
- Sergey DevitskiyLebanon$192
- Elizabeth BengtsonLebanon$120
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.